MEDICINOVA INC
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
MNOV$1.40-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
| Years ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating activities: | ||
| Net loss | $(8,571,516) | $(14,069,083) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Non-cash stock-based compensation | 710,710 | 642,522 |
| Depreciation and amortization | 20,295 | 17,707 |
| Non-cash interest on investments | (346,390) | (154,003) |
| Loss on disposal of investments | 448,903 | 122,475 |
| Loss on disposal of property and equipment | 472 | — |
| Change in carrying amount of right-of-use asset | 194,502 | 194,719 |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other assets | 287,628 | 150,605 |
| Accounts payable, accrued liabilities and other liabilities | 19,238 | 329,010 |
| Operating lease liabilities | (194,880) | (145,515) |
| Net cash used in operating activities | (7,431,038) | (12,911,563) |
| Investing activities: | ||
| Purchases of investments | — | (59,877,526) |
| Proceeds from disposal of investments | 39,929,015 | 19,877,526 |
| Acquisitions of property and equipment | (21,299) | (5,010) |
| Net cash provided by (used in) investing activities | 39,907,716 | (40,005,010) |
| Financing activities: | ||
| Proceeds from issuance of common stock and exercise of common stock options | — | 7,920 |
| Net cash provided by financing activities | — | 7,920 |
| Effect of exchange rate changes on cash and cash equivalents | 17,271 | (16,808) |
| Net change in cash and cash equivalents | 32,493,949 | (52,925,461) |
| Cash and cash equivalents, beginning of year | 18,505,493 | 71,430,954 |
| Cash and cash equivalents, end of year | $50,999,442 | $18,505,493 |
| Supplemental disclosure of cash flow information: | ||
| Right-of-use asset obtained in exchange for operating lease liability | $139,001 | $— |
| Income taxes paid | $3,667 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.